I'm just one person, just two hands, just one heart. I have everything to offer.


This blog brings together resources and stories for other young caregivers and families dealing with the effects of Alzheimer's and the many OTHER forms of dementia including Dementia with Lewy Bodies, Creutzfeldt-Jakob Disease, Frontal Lobe Dementia, Huntington’s Disease , Parkinson’s Disease, Mild Cognitive Impairment, Wernicke-Korsakoff Syndrome, Mixed Dementia, Normal Pressure Hydrocephalus, Pick’s Disease and Vascular Dementia.


Showing posts with label Public Policy. Show all posts
Showing posts with label Public Policy. Show all posts

Thursday, May 7, 2015

Reposted: Who Am I Now That She’s Gone

From one of my best friends, and one of the strongest women I know, Kathy Ritchie www.MyDementedMom.com

There are a lot of similarities between a small child and someone living with dementia. Specifically, frontotemporal degeneration. I remember so many of my mom’s odd quirks. Once, she poured her Coke into her glass of red wine. She drank it, much to my dismay. My toddler did something similar recently. She poured water into a bowl of hard boiled eggs then she mixed it around and ate it. I immediately thought of my mom. I can’t remember if I laughed or felt sad. Her disease caused her to mentally and emotionally regress… a real life Benjamin Button. I always thought having a young child would be, in some ways, easier than having a mother with dementia. In some ways it is: there’s so much more joy, more laughter, fewer tears. My toddler is also considerably lighter than my mother, and when she is upset or angry, I can actually pick her up and hold her… or relocate her. Something I wasn’t exactly able to do with mom (remember those times with her priest?). Lately though, I have been missing my mom; missing something about her… I can’t quite put my finger on the what. Maybe just her presence. Her scent…. I don’t know. I lost my mom, really, when I was in my 20s… I became the parent and she became the child. Before that, I was living in another city thousands of miles from home. I feel guilty about that. Maybe if I had stayed in Arizona, maybe I would have had more of those moments… precious moments that would have stuck with me, helped shape me into someone better that who I became. Instead, my memories are blurry… sometimes I’ll hear something or get a whiff of something and it’ll transport me to a particular time or place… but they’re few and far between. And sometimes I’ll dream about her. Those are the sweetest nights. I wish she came to me more often.

And then there are times when I can’t feel her at all. The loneliness is palpable.

I thought I would be relieved when my mom died. I was in most ways. I was glad she was no longer suffering in a broken down body. I was glad to put that chapter behind me and focus on my baby. I thought the hurt would fade away, too. Time does some neat tricks when it wants to, and frankly, I lost my mom a long time ago. But what I’m learning is that this kind of loss sticks with you. I know it has changed me. And I don’t know if it’s for the better. The final years were incredibly brutal and how one recovers from such a trauma is beyond me. To wallow in it would be selfish and indulgent, though there are days where I wish I could stew in it. So I try to keep going. I hate when things become stagnant. When that happens I desperately seek change. Is this blog, is the work that I do to share our story stagnant? I mean what else is there to say? Is it — this — the anchor holding me down or the means to truly let go. I have no idea what any of it means or if it means anything at all. I guess the truth is I don’t know who I am anymore now that she is gone.

That’s a little lonely, too.

Sunday, March 10, 2013

We’re Young, We’re Poor, & We Need a Cure. Our Lives Depend on It


By my friend and fellow young advocate, Kathy Ritchie
As I write this blog, I’m trolling Twitter. Just seeing what’s out there in the way of caregiver support, resources, news, etc, etc, etc. Turns out, there’s a lot shaking in our world. A quick scroll on my feed shows Tweets about everything from incontinence and nursing homes to tips on how to be an organized caregiver (“organized” and “caregiver:” two words that don’t really go together). Lots of information. Some of it useful; most of it scary.
(No, you don’t and won’t have enough money to grow old).
While you’ll absolutely find information about caregiving or being a caregiver, much of what’s out there is geared towards Baby Boomers… because let’s face it, Baby Boomers are a hot commodity right now.
Why? They’re rich and they’re going to get sick.
As for the under 40 set, well, we’re sort of preoccupied with paying off our student loans, buying our first home (or drowning in it, as the case may be), finding our dream job, finding Mr. or Ms. Right, making babies, having babies and/or getting divorced.
You know what else we’re doing? We’re NOT saving. Saving for the day we develop a long term illness like dementia.
That said, we’re about as undesirable as they come. And you should be pissed off about that. After all, we’re not safe from Alzheimer’s disease or other dementias… there are no cures, no means of prevention. NADA.
Still not convinced? Just Google, “Alzheimer’s and 2050.”
This is the quiet before the Tsunami.
Here are a few things you should know:
  • Alzheimer’s disease is just one of several types of dementias (my mom has frontotemporal dementia).
  • HIV/AIDS was once considered a death sentence; today it’s a “manageable disease.” That’s because a lot of money was thrown into the research bucket and antiviral drugs were developed.
  • Medicare will NOT pay for nursing home/assisted living care.
  • You can’t afford to grow old. According to Genworth’s 2012 Cost of Care Survey, which I found in an online article on Next Avenue,  “one year of long-term care ranges from $39,600 for an assisted living facility to $81,030 for a private room in a nursing home.” (source: Next Avenue; Genworth)
  • Alzheimer’s disease is the sixth-leading cause of death in the U.S. and the only cause of death among the top 10 in the United States that cannot be prevented, cured or even slowed. (source: 2012 Alzheimer’s Association, Facts & Figures report)
  • Have you ever changed an adult’s diaper? More than 15 million Americans provide unpaid care valued at $210 billion for persons with Alzheimer’s and other dementias.  (source: 2012 Alzheimer’s Association, Facts & Figures report)
  • In 2012, the direct costs of caring for those with Alzheimer’s or other dementias to American society will total an estimated $200 billion, including $140 billion in costs to Medicare and Medicaid. Unless something is done, the care costs of Alzheimer’s and other dementias will soar from $200 billion to a projected $1.1 trillion (in today’s dollars) by 2050.  (source: 2012 Alzheimer’s Association, Facts & Figures report)
What can you (reasonably) do?
Here’s the myth: Alzheimer’s disease and other dementias are diseases old people get. Here’s the truth: People in their 30s, 40s and 50s are developing dementia. Here’s the other truth: This disease will touch your life one day, if it hasn’t already.
Dementia is not an old person’s disease.

Friday, May 25, 2012

A New Attack on Alzheimer’s

The Obama administration has announced a bold research program to test whether a drug can prevent the onset of Alzheimer’s disease well before any symptoms appear. It is a long shot, but the payoff could be huge.

The prevailing, but not universally accepted, hypothesis is that amyloid plaques in the brain play a major role in causing Alzheimer’s. Crenezumab attacks the formation of such plaques, apparently by binding to amyloid proteins and clearing them from the brain. If the drug fails to work, the trial will probably demolish the amyloid hypothesis and set researchers scrambling to find other targets to attack.
Currently, there is no cure for Alzheimer’s, which steadily robs patients of their memory, followed by full-blown dementia. There is also no diagnostic test to identify who has it, and no treatment to slow patients’ deterioration for more than a few months. 
 
While work continues on those fronts, the new clinical trial will test whether the drug, Crenezumab, made by Genentech, can prevent the disease in a group of people whose genetic heritage guarantees that they will develop it. If the drug successfully prevents the loss of mental capacities as measured by a sensitive new cognitive test there is hope — but no guarantee — that it could do the same for members of the general public. As Pam Belluck described in The Times last week, the trial will focus on members of an extended family in Colombia who carry a rare genetic mutation that causes them to develop Alzheimer’s early in life. They typically experience cognitive impairment at about age 45 and dementia by 51. The trial will also include a smaller number of individuals in the United States with the same genetic mutation. 

Instead of recruiting thousands of volunteers and following them for an extended period as in a customary prevention trial, the researchers in Colombia will give the drug to only 100 people with the early-onset genetic mutation. They will give placebos to another 100 people with the mutation and to 100 family members who do not carry the deadly gene. 

The study will cost more than $100 million and is being financed mostly by Genentech, buttressed by $16 million from the National Institutes of Health and $15 million raised by the Banner Alzheimer’s Institute in Phoenix, which is leading the study. 


A prevention trial of a different drug that was also intended to slow formation of amyloid plaques actually made patients’ symptoms worse, possibly because it interfered with various other proteins needed by the brain. Researchers believe that Crenezumab will be safer and more effective, but again there are no guarantees. The risk is justified given that without the treatment the recipients will inevitably get Alzheimer’s in the prime of their lives. The truly big payoff will come if the drug succeeds in this group and lays the groundwork for preventing or slowing the progress of Alzheimer’s that appears late in life. The researchers will be gathering data on a variety of biomarkers — glucose activity in the brain, shrinkage of the brain, certain proteins in cerebral spinal fluid, for example — to see which if any are related to preventing amyloid plaques and the loss of mental abilities. 

If the drug prevents the deterioration of particular biomarkers and ultimately sustains mental capacity, then the same markers might be useful in identifying and treating older people likely to develop the disease. And federal regulators might be willing to approve other prevention drugs based on their short-term effects on biomarkers, speeding the conduct of clinical trials. 

More than five million Americans currently have Alzheimer’s. Without an effective preventive, the number will rise steadily as the population ages. 

Published: May 20, 2012  by NY Times, Editorial

Thursday, January 6, 2011

National Alzheimer’s Project Act (NAPA) Becomes Law

Landmark legislation passes

The National Alzheimer's Project Act (NAPA) is the largest legislative victory in many years for the Alzheimer cause. Over the last several years, the Alzheimer's Association has been the leading voice in urging Congress and the White House to pass the National Alzheimer's Project Act (NAPA). The National Alzheimer's Project Act will create a coordinated national plan to overcome the Alzheimer crisis and will ensure the coordination and evaluation of all national efforts in Alzheimer research, clinical care, institutional, and home- and community-based programs and their outcomes. Alzheimer's advocates were instrumental in moving NAPA through Congress. More than 50,000 e-mails, nearly 10,000 phone calls and more than 1,000 meetings by the Alzheimer's Association and its advocates led us to the historic legislative victory for the Alzheimer community.

NAPA Chronology

January 4, 2011 President Obama signs NAPA into law, marking the largest legislative victory in many years for the Alzheimer cause.
Late December Alzheimer's Association advocates have sent more than 15,000 email messages to the White House asking the President to sign the National Alzheimer's Project Act into law.
December 15, 2010 Thousands of advocates flood Capitol Hill with phone calls and e-mails urging their Representatives to vote for NAPA. NAPA is passed by the House of Representatives and moves to the White House for signature.
December 9, 2010 Alzheimer's Association President and CEO Harry Johns testified before the House Committee on Energy and Commerce, Subcommittee on Health. Harry spoke about the importance of NAPA and encouraged its immediate passage.
December 8, 2010 After Alzheimer's Association advocates blanket Senate offices with phone calls and e-mails for several days, asking the Senate to pass NAPA immediately, the National Alzheimer's Project Act (S.3036) passed the Senate unanimously and moved to the House of Representatives.
December 1, 2010 After months of behind the scenes work by the Alzheimer's Association federal affairs team with champions in Congress, the Senate Committee on Health, Education, Labor, and Pensions (HELP) approved the National Alzheimer's Project Act (S. 3036).
October 18, 2010 With the release of The Shriver Report: A Woman's Nation Takes on Alzheimer's Disease, repeated appeals are made for the passage of NAPA in Hill visits, Administration briefings, Washington policy briefings, and by Maria Shriver in interviews on This Week and other news programs.
September 21, 2010 Concluding the Alzheimer's Breakthrough Ride, on World Alzheimer's Day participants cycled to Capitol Hill and presented more than 110,000 petition signatures for delivery to Congress. The petition called for passage of the National Alzheimer's Project Act and two other Alzheimer's Association priorities.

Researchers who participated in the Alzheimer's Breakthrough Ride visited Capitol Hill to meet with more than 50 Members of Congress, urging their support for NAPA.

Later that day, the Alzheimer's Association delivered a message in support of NAPA at a special White House briefing on Alzheimer's disease. Harry Johns, Alzheimer's Association President and CEO, and National Board Member Stephen Hume, Psy.D., an individual living with the disease, made presentations at the meeting, focusing on the urgent need for a coordinated national Alzheimer's strategy and for its swift implementation. See the full video of the White House meeting.
July 30, 2010 The Alzheimer's Association President and CEO Harry Johns, former National Board Public Policy Chair Bettylu Saltzman, and Public Policy Vice President Robert Egge meet again with Pete Rouse, one of President Obama's top aides, to solicit the Administration's support for NAPA and for creating a national strategy to combat Alzheimer's disease.
Summer 2010 The Alzheimer's Association's President and CEO, Harry Johns, and the federal affairs team make the rounds on Capitol Hill, meeting with members of Congress and staff to drum up support for NAPA and to plan strategy on how to enact the bill by the end of the year.
March 9, 2010 Alzheimer's Association Advocacy Forum attendees march on Capitol Hill to meet with their Members of Congress, urging their support for the National Alzheimer's Project Act.


David Hyde Pierce joins advocates from Iowa to meet with Sen. Chuck Grassley (R-Iowa).
February 2, 2010 With active collaboration and drafting support from the Alzheimer's Association, the National Alzheimer's Project Act is reintroduced by Senator Evan Bayh and Senator Susan Collins in the Senate (S.3036) and by Rep. Ed Markey and Rep. Chris Smith (H.R.4689) in the House. The Alzheimer's Association immediately endorses the reintroduced bill.
July 31, 2009 Based on the Alzheimer's Study Group recommendations and following consultations with the Alzheimer's Association, Sen. Mel Martinez introduces the first National Alzheimer's Project Act in Congress. The Alzheimer's Association immediately endorses the bill.
July 20, 2009 The Alzheimer's Association President and CEO Harry Johns, former National Board Public Policy Chair Bettylu Saltzman, and Public Policy Vice President Robert Egge meet with Pete Rouse, one of President Obama's top aides, to discuss the Alzheimer's crisis and introduce the need for a bold, coordinated national Alzheimer strategy to address it.
March 25, 2009 Alzheimer's Study Group releases its final report, A National Alzheimer's Strategic Plan: The Report of the Alzheimer's Study Group. The report calls for the creation of a National Alzheimer's Strategy and an Alzheimer's Project Office within the federal government. Harry Johns, President and CEO of the Alzheimer's Association, pledged, "You can be assured that the Alzheimer's Association will play a leading role in seeking the enactment of the core recommendations present in the ASG report."

That same day, advocates attending the 2009 Alzheimer's Association Advocacy Forum visited their Members of Congress urging support for these key Alzheimer's Study Group recommendations, the beginning of the Association's ongoing campaign to accomplish this objective in the 111th Congress.

Register now to attend the 2011 Alzheimer's Association Advocacy Forum.
July 11, 2007 With endorsement of, and financial and in-kind support from, the Alzheimer's Association, the Alzheimer's Study Group is launched at a Capitol Hill Conference. The Alzheimer's Study Group is also endorsed at the launch event by then Alzheimer's Disease Task Force co-chairs, then-Senator Hillary Clinton and Senator Susan Collins, and Rep. Ed Markey and Rep. Chris Smith, as well as by Senator Barbara Mikulski and Senator Richard Burr.
July 2007 Speaker Newt Gingrich and Robert Egge author an article in Alzheimer's and Dementia: The Journal of the Alzheimer's Association. This article, "Developing a National Alzheimer's Strategy Equal to the Epidemic," first makes the case for the creation of a federal Alzheimer strategy.